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Previewshow IDE functions in health and its linkage
to diabetes, as well as whether the postu-
lated role of IDE as a defender against
amyloidogenic protein-induced toxicity
is valid.
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Bile acid metabolism is tightly controlled due to the toxic effects of bile acid overload. In this issue, research
from the Feng lab reports Shp2 as a novel integrator of hepatic bile acid and FGF15/FGF19 signaling, adding
another layer of complexity to the control of bile acid biosynthesis.Bile acids (BAs) are end products of
cholesterol metabolism but also well-
recognized signaling molecules. They are
synthesized from cholesterol in the liver,
secreted from hepatocytes into bile, and
stored in the gallbladder. After ingestion
of a meal, bile is secreted into the small
intestine, where BAs contribute to the
solubilization and absorption of lipids and
fat-soluble vitamins. The majority of BAs
are reabsorbed in the terminal ileum and
transported back to the liver via the portal
vein in a process defined as enterohepatic
circulation (Thomas et al., 2008). BAs that
escape intestinal absorption are excreted
in the feces, thus removing the excess
cholesterol from the body. Despite their
essential functions, high levels of BAs
and cholesterol contribute to multiple hu-
man metabolic diseases, including chole-
cystolithiasis (gallstones), hepatic chole-
stasis, and atherosclerosis, emphasizing
the need for a tight regulation of BA syn-
thesis. In this issue of Cell Metabolism,
Li and coauthors (Li et al., 2014) identify
Shp2 as a novel coordinator of BA homeo-stasis in the liver, adding an additional
layer of complexity to this process.
Besides their role in dietary lipid ab-
sorption, BAs function as signaling mole-
cules that activate specific receptors,
including the nuclear farnesoid X receptor
(FXR or NR1H4) and the G protein-
coupled receptor TGR5 (Thomas et al.,
2008). FXR is the major regulator of the
negative feedback loop that controls BA
synthesis. Indeed, BA-activated FXR in-
duces hepatic expression of the small
heterodimer partner (SHP or NROB2), an
atypical nuclear receptor that suppresses
BA biosynthesis by inhibiting the expres-
sion of Cyp7a1, which encodes for the
rate-limiting enzyme of this pathway. A
second mechanism for the inhibition of
BA production involves intestinal BA-
FXR signaling. Activation of enteric FXR
by BAs leads to a robust induction and
secretion of fibroblast growth factor 15/
19 (FGF15 in mouse and FGF19 in human)
(Inagaki et al., 2005). FGF15/19 is
released into the circulation and binds
to the FGFR4/b-Klotho complex on thehepatocyte cell membrane, triggering
an intracellular signaling cascade that
represses Cyp7a1 mRNA expression
and BA synthesis. Although the precise
molecular mechanisms are not yet
completely characterized, several lines
of evidence indicate that both the liver re-
ceptor homolog 1 (LRH-1 or NR5A2) and
the hepatocyte nuclear factor 4a (HNF4a
or NR2A1) are crucial transcriptional
activators of the Cyp7a1 promoter and
are required for FGF15/19 and SHP to
repress Cyp7a1 (Kir et al., 2012; Nitta
et al., 1999; Stroup and Chiang, 2000).
It has been proposed that BA-induced
FGF15/19 increases the stability of
hepatic SHP by inhibiting its proteaso-
mal degradation in an extracellular
signal-regulated kinase (ERK)-dependent
manner (Miao et al., 2009), yet other
studies suggest that FGF15/19 treatment
does not alter the affinity of SHP, HNF4a,
and LRH-1 to the Cyp7a1 promoter (Kir
et al., 2012).
Within this scenario, Li et al. identified
the Src-homology 2 domain-containing0, August 5, 2014 ª2014 Elsevier Inc. 203
Figure 1. Hepatic FGF15/19-Shp2 Signaling Represses Bile Acid Synthesis
Bile acids (BAs) are synthesized from cholesterol in the liver, and this mechanism is tightly regulated
through control of the rate-limiting enzyme Cyp7a1. In response to a meal, BAs are released in the
circulation and act in the intestine to increase FGF15/19 levels in a FXR-dependent manner. In turn,
FGF15/19 activates a negative feedback loop through the FGFR4/b-Klotho receptor to inhibit BA
synthesis. The tyrosine phosphatase, Shp2, binds to the FGFR4/b-Klotho complex and is essential for
the proper transduction of FGF15/19 signaling.
Cell Metabolism
Previewstyrosine phosphatase 2 (Shp2) as a crit-
ical signaling component of the hepatic
response to control BA biosynthesis
via FGF15/19 and BA-FXR signaling
(Li et al., 2014). Mice lacking Shp2 in
their hepatocytes (Shp2hep/) exhibit all
the hallmarks of an impaired ability to
repress hepatic BA synthesis, including
BA overproduction, increased plasma
BA levels, and fecal BA excretion, as
well as reduced plasma cholesterol levels.
Bile duct ligation dramatically worsened
these defects, and Shp2hep/ mice died
within 4 weeks due to enlarged gallblad-
ders and more severe jaundice, asso-
ciated with massive hepatic necrosis
and liver failure. All these hepatobiliary
dysfunctions were dependent on the
excess of BAs since they were greatly
attenuated after administration of the204 Cell Metabolism 20, August 5, 2014 ª201BA sequestrant, cholestyramine. From
a mechanistic point of view, deletion
of Shp2 resulted in an increased expres-
sion of key genes involved in BA bio-
synthesis, including Cyp7a1, Cyp8b1,
and Cyp27a1, and a defective FXR-
dependent upregulation of SHP. In
addition, Li et al. demonstrated that
Shp2 acts as a regulator of the tyrosyl
phosphorylation of FGFR4 and of its
immediate target FRS2a, thus being
essential for the FGF15/19-mediated
activation of the FGFR4/P-ERK1/2/PKC
signaling pathway (Figure 1). In fact,
raising the intrahepatic BA levels by bile
duct ligation or intraperitoneal injection
of hFGF19 failed to effectively suppress
BA synthesis in Shp2hep/ mice. These
observations pinpoint Shp2 as a novel
positive regulator of the hepatic response4 Elsevier Inc.to both intrahepatic and ileal inhibitory
signals.
These pieces of evidence demonstrate
that a tight regulation of BA synthesis
is required. Although both FXR/SHP-
and FXR/FGF15/19-activated signaling
pathways play important roles in the
repression of BA synthesis, their relative
physiological importance in humans re-
mains to be determined. Human genetic
studies to explore whether variants in
genes of Shp2 signaling components
correlate with BA levels or are linked
with diseases of BA homeostasis are
therefore of relevance. For instance,
elevation of BA levels seen subsequent
to liver damage promotes liver regrowth
and regeneration, thereby compensating
for the BA overload (Huang et al., 2006).
Given the role of Shp2 as both a liver
tumor suppressor (Bard-Chapeau et al.,
2011) and as a feedback regulator of BA
production, the link between BAs, Shp2,
and hepatocellular carcinoma should be
explored. Apart from its function in the
liver, Shp2 is a master regulator of meta-
bolism. Indeed, deletion of Shp2 in the
adult brain resulted in the development
of early-onset obesity, with increased lep-
tin resistance and liver steatosis (Zhang
et al., 2004). It will be interesting to assess
to what extent disruption of Shp2 may
affect other metabolic organs and how
this may affect parallel GPCR-activated
BA signaling pathways, such as those
controlled by TGR5.
In summary, Li et al. (2014) clearly
demonstrate that altered BA homeo-
stasis, secondary to loss of Shp2
function and abnormal FGF15/19 sig-
naling, evolves to chronic hepatobiliary
disorders in mice. These findings add
a further layer of complexity to the
already well-studied signaling pathways
that control BA homeostasis. The link
between BA and metabolic regulation
is well established, but a better under-
standing of the function and cooperation
of each protein involved in the control of
BA metabolism could have important
therapeutic implications for hepatobiliary
disorders as well as for metabolic dis-
eases and cancer.
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Activation of dorsomedial hypothalamic-rostral medullary raphe neural signaling promotes brown fat ther-
mogenesis, leading to elevated body temperature. In this issue, Kataoka et al. (2014) establish an important
role for this brain-brown fat thermogenic action in psychological stress-induced hyperthermia in rats,
implying a potential mechanism behind human psychogenic fever.Psychological stress-induced hyperther-
mia (PSH) or ‘‘psychogenic fever’’ result-
ing from various types of psychological
stress has long been noted (Falcon-Les-
ses and Proger, 1930; Oka et al., 2001),
but the neural mechanism linking psy-
chological stress to an acute or chronic
elevation of body temperature (hyper-
thermia or fever) remains unclear. Brown
adipose tissue (BAT) is a nonshivering
thermogenic organ in mammals and
acts to dissipate chemical energy to pro-
duce heat for protection against a cold
environment (Cannon and Nedergaard,
2004). BAT thermogenesis also contrib-
utes to pyrogen-induced fever (Jepson
et al., 1988; Sze´kely et al., 1973), a febrile
response of the body that aims to in-
crease immune cell activity and suppress
pathogen growth for fighting against in-
fections. The sympathetic nervous sys-
tem (SNS) stimulates BAT thermogenesis
in response to cold or pyrogenic stim-
ulus, and this stimulation is regulated by
the central nervous system (Morrison
et al., 2014). Although detailed central
regulation of BAT thermogenesis and
body temperature remains incompletely
defined, recent evidence has indicateda critical role for the hypothalamic-med-
ullary signaling pathway in thermoregula-
tion (Dimicco and Zaretsky, 2007; Morri-
son et al., 2014; Saper et al., 2012).
Specifically, the hypothalamic preoptic
area (POA) contains temperature-sensi-
tive neurons that integrate central and
peripheral thermal signals, which are
then relayed via the dorsomedial hypo-
thalamus (DMH) to the rostral medullary
raphe (RMR) in order to activate the
SNS and regulate body temperature
(Figure 1). In this issue, Kataoka et al.
(2014) provide evidence that the DMH-
RMR-BAT thermogenic system contrib-
utes to psychological stress-induced
hyperthermia.
To explore a potential neural mecha-
nism underlying PSH, Kataoka and col-
leagues (2014) exposed rats to social
stress by placing ‘‘intruder’’ rats into
the cages of dominant resident rats.
They found that the defeated intruders
had significant elevations of interscapu-
lar BAT (IBAT) and core body tempera-
ture, demonstrating that social defeat
stress induces hyperthermia in rats.
Since the SNS mediates BAT thermo-
genesis via b3-adrenergic receptors(Cannon and Nedergaard, 2004), the au-
thors next pharmacologically blocked
sympathetic signaling to assess whether
social defeat stress-induced hyperther-
mia is mediated through sympathetic
BAT thermogenesis. In support of their
view, intravenous injection of the nonse-
lective b-blocker propranolol into the in-
truders prior to the stress exposure
significantly eliminated stress-induced
increases in IBAT and body tempera-
ture. Thus, the results from this study
and their previous report showing the
similar effect of b3-receptor-specific
antagonist indicate a primary role for
BAT thermogenesis in social defeat
stress-induced hyperthermia (Kataoka
et al., 2014).
The authors then sought to charac-
terize the neural circuit underlying this
phenomenon. They found that both inhi-
bition of neurons in the RMR with a
GABAA receptor agonist and blockade
of glutamate receptors in the RMR by
glutamate receptor antagonists signifi-
cantly reduced social stress-induced in-
creases in IBAT and body temperature
(Kataoka et al., 2014). These results
establish that glutamatergic inputs into0, August 5, 2014 ª2014 Elsevier Inc. 205
